- Business Wire•5 days agoAeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium
Aeterna Zentaris Inc. today announced that a poster entitled, “A phase II trial of zoptarelin doxorubicin in castration-and taxane-resistant prostate cancer”, will be presented during the 2017 Genitourinary Cancers Symposium’s “Translating Research to Value-based and Patient-centric Care” by lead investigator, and co-author of the presentation, Jacek Pinski, MD, PhD, USC Norris Comprehensive Cancer ...
- Business Wire•7 days ago
Aeterna Zentaris Inc. today announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial of Macrilen™ for the evaluation of growth hormone deficiency in adults , using the insulin tolerance test as a comparator, it concluded that Macrilen™ demonstrated performance supportive of achieving registration with the U.S.
- Business Wire•11 days ago
Aeterna Zentaris Inc. , announced today that it will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 9:30 AM EST.
AEZS : Summary for Aeterna Zentaris Inc. - Yahoo Finance
Aeterna Zentaris Inc. (AEZS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.80 x 1000|
|Ask||6.50 x 300|
|Day's Range||3.30 - 3.45|
|52 Week Range||2.35 - 5.59|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.15|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|